This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Company Statement: U.S. Federal Trade Commission clears Teva's acquisition of Cephalon

( October 7, 2011, 21:13 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals has announced the Federal Trade Commission conditionally approved its buy of Cephalon. The companies must sell two new drug applications, one for cancer pain drug that is a generic version of Actiq, and another for a muscle relaxer which is the generic version of Amrix. The third and final divestiture includes a supply agreement of the generic version of narcolepsy treatment drug Provigil. The deal still requires approval from the European Commission, but the companies expect to close by October 14.Company press release follows in full:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login